Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer.
Aged
Aged, 80 and over
CD4-Positive T-Lymphocytes
/ immunology
Colorectal Neoplasms
/ genetics
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
/ immunology
Humans
Inflammation
/ immunology
Interleukin-1
/ immunology
Male
Middle Aged
Tertiary Lymphoid Structures
/ immunology
Tumor Microenvironment
/ genetics
Colorectal cancer
Interleukin (IL)-36 g
M1 classically activated macrophages
Memory T cells
Tertiary lymphoid structure
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
23
02
2018
accepted:
04
10
2018
pubmed:
14
10
2018
medline:
29
1
2019
entrez:
14
10
2018
Statut:
ppublish
Résumé
IL-1 family cytokines play a dual role in the gut, with different family members contributing either protective or pathogenic effects. IL-36γ is an IL-1 family cytokine involved in polarizing type-1 immune responses. However, its function in the gut, including in colorectal cancer pathogenesis, is not well appreciated. In a murine model of colon carcinoma, IL-36γ controls tertiary lymphoid structure formation and promotes a type-1 immune response concurrently with a decrease in expression of immune checkpoint molecules in the tumor microenvironment. Here, we demonstrate that IL-36γ plays a similar role in driving a pro-inflammatory phenotype in human colorectal cancer. We analyzed a cohort of 33 primary colorectal carcinoma tumors using imaging, flow cytometry, and transcriptomics to determine the pattern and role of IL-36γ expression in this disease. In the colorectal tumor microenvironment, we observed IL-36γ to be predominantly expressed by M1 macrophages and cells of the vasculature, including smooth muscle cells and high endothelial venules. This pattern of IL-36γ expression is associated with a CD4
Identifiants
pubmed: 30315348
doi: 10.1007/s00262-018-2259-0
pii: 10.1007/s00262-018-2259-0
pmc: PMC7185158
mid: NIHMS1524750
doi:
Substances chimiques
IL36G protein, human
0
Interleukin-1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109-120Subventions
Organisme : National Institutes of Health
ID : CA204419
Organisme : Cancer Research for Personalized Medicine
ID : CARPEM T8
Organisme : Cancer Research for Personalized Medicine
ID : Doctorate Fellowship
Organisme : Agence Nationale de la Recherche
ID : LAXE62_9UMRS972 FRIDMAN
Organisme : NCI NIH HHS
ID : R01 CA204419
Pays : United States
Organisme : Embassy of France in the United States
ID : STEM Chateaubriand Fellowship
Organisme : National Institutes of Health
ID : CA169118
Organisme : NCI NIH HHS
ID : R01 CA169118
Pays : United States
Organisme : Institut National Du Cancer
ID : C1608DS
Références
PLoS One. 2015 Nov 12;10(11):e0138423
pubmed: 26562662
Surg Oncol Clin N Am. 2017 Oct;26(4):689-704
pubmed: 28923225
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
Exp Dermatol. 2017 May;26(5):402-408
pubmed: 27673278
J Biol Chem. 2012 Dec 7;287(50):41684-96
pubmed: 23095752
Clin Cancer Res. 2017 Aug 1;23(15):4416-4428
pubmed: 28213366
Cancer Immunol Res. 2015 Jan;3(1):1-11
pubmed: 25568067
PLoS One. 2014 Jun 06;9(6):e99008
pubmed: 24905750
Cancer Res. 2011 Sep 1;71(17):5678-87
pubmed: 21846823
J Allergy Clin Immunol. 2010 Nov;126(5):898-907; quiz 908-9
pubmed: 21050940
J Clin Oncol. 2008 Sep 20;26(27):4410-7
pubmed: 18802153
Cancers (Basel). 2011 Dec 28;4(1):1-10
pubmed: 24213222
Cytometry A. 2011 Feb;79(2):167-74
pubmed: 21265010
Blood. 2012 Oct 25;120(17):3478-87
pubmed: 22968459
PLoS Med. 2013;10(5):e1001453
pubmed: 23700391
Am J Cancer Res. 2011;1(4):482-97
pubmed: 21984967
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Physiol Genomics. 2014 Apr 1;46(7):223-44
pubmed: 24520152
Bull Cancer. 2017 Jan;104(1):20-29
pubmed: 28007294
Cardiovasc Res. 2014 Mar 1;101(3):434-43
pubmed: 24272771
Front Med (Lausanne). 2015 Sep 22;2:69
pubmed: 26442271
Patient Relat Outcome Meas. 2015 May 18;6:127-38
pubmed: 26056501
Cancer Res. 2011 Oct 15;71(20):6391-9
pubmed: 21900403
Clin Cancer Res. 2013 Aug 1;19(15):4079-91
pubmed: 23785047
Oncoimmunology. 2017 Apr 28;6(6):e1322238
pubmed: 28680760
Blood. 2011 Nov 24;118(22):5813-23
pubmed: 21860022
Clin Cancer Res. 2014 Apr 15;20(8):2147-58
pubmed: 24523438
Eur J Immunol. 2012 Mar;42(3):607-17
pubmed: 22144259
Br J Cancer. 2013 May 28;108(10):2106-15
pubmed: 23652304
Genomics. 2000 Jun 1;66(2):213-6
pubmed: 10860666
PLoS One. 2014 Jun 19;9(6):e99955
pubmed: 24945657
Cytokine. 2016 Sep;85:18-25
pubmed: 27269181
Clin Exp Immunol. 2009 Jun;156(3):479-87
pubmed: 19438601
J Immunol. 2001 Aug 1;167(3):1440-6
pubmed: 11466363
J Immunol. 2014 Jun 15;192(12):6053-61
pubmed: 24829417
Genome Biol. 2016 Oct 20;17(1):218
pubmed: 27765066
Cytokine. 2016 Aug;84:88-98
pubmed: 27259168
Cancer Sci. 2017 Jun;108(6):1128-1134
pubmed: 28370718
Front Pharmacol. 2014 May 27;5:123
pubmed: 24904424
Immunol Rev. 2016 May;271(1):260-75
pubmed: 27088920
Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44
pubmed: 24484236
J Biol Chem. 2004 Apr 2;279(14):13677-88
pubmed: 14734551
Int J Clin Exp Pathol. 2014 Oct 15;7(11):8077-81
pubmed: 25550854
Gut. 2017 May;66(5):823-838
pubmed: 26783184
Am J Pathol. 2011 Jul;179(1):37-45
pubmed: 21703392
Immunity. 2016 Mar 15;44(3):450-462
pubmed: 26982353
Biostatistics. 2010 Apr;11(2):242-53
pubmed: 20097884
Clin Cancer Res. 2016 Aug 15;22(16):4057-66
pubmed: 26994146
Gastroenterology. 2010 Mar;138(3):958-68
pubmed: 19914252